The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Targeting HER2-positive metastatic breast cancer with ARX788, a novel anti-HER2 antibody-drug conjugate in patients whose disease is resistant or refractory to T-DM1, and/or T-DXd, and/or tucatinib-containing regimens.
 
Janice M. Lu
Honoraria - AstraZeneca/Daiichi Sankyo; Lilly; Pfizer; Sanofi/Aventis; Seagen
Consulting or Advisory Role - AstraZeneca/Daiichi Sankyo; Lilly; Novartis; Pfizer; Sanofi/Aventis
Research Funding - Ambrx (Inst); Genentech (Inst); Lilly (Inst); Novartis (Inst); Radius Health (Inst)
 
Kevin Kalinsky
Stock and Other Ownership Interests - Array BioPharma (I); GRAIL (I); Pfizer (I)
Consulting or Advisory Role - 4D Pharma; AstraZeneca; bioTheranostics; Cyclacel; Daiichi Sankyo/Astra Zeneca; Eisai; Genentech/Roche; immunomedics; Ipsen; Lilly; Merck; mersana; Novartis; Oncosec; pfizer; Puma Biotechnology; Seagen
Speakers' Bureau - Lilly
Research Funding - Acetylon Pharmaceuticals (Inst); Amgen (Inst); Calithera Biosciences (Inst); CytomX Therapeutics (Inst); Genentech/Roche (Inst); Immunomedics (Inst); incyte (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Seagen (Inst); Zeno Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Lilly; Pfizer
Other Relationship - Genentech; Immunomedics
 
Debu Tripathy
Consulting or Advisory Role - AstraZeneca; Genomic Health; GlaxoSmithKline; Novartis; OncoPep; Pfizer
Research Funding - Novartis (Inst); Pfizer (Inst); Polyphor (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Novartis
 
George W. Sledge
Leadership - Syndax; Tessa Therapeutics
Stock and Other Ownership Interests - Pionyr; Syndax; Tessa Therapeutics
Consulting or Advisory Role - AstraZeneca; Caris Life Sciences; G1 Therapeutics; GRAIL; Synaffix; Syndax; Verseau Therapeutics
Research Funding - Genentech/Roche (Inst); Pfizer (Inst); QED Therapeutics (Inst)
Travel, Accommodations, Expenses - Caris Life Sciences; Tessa Therapeutics; Verseau Therapeutics
 
William John Gradishar
Consulting or Advisory Role - AstraZeneca; BeyondSpring Pharmaceuticals; Genentech/Roche; merck; Pfizer; Puma Biotechnology; Seagen
 
Ruth O'Regan
Honoraria - AstraZeneca/MedImmune; bioTheranostics; Genentech; Immunomedics; Lilly; Macrogenics; Novartis; Pfizer; Puma Biotechnology; Seagen
Consulting or Advisory Role - AstraZeneca/MedImmune; bioTheranostics; Genentech; ImmunogenX; Lilly; Macrogenics; Novartis; Puma Biotechnology; Seagen
Research Funding - Novartis (Inst); Puma Biotechnology (Inst)
 
Joyce O'Shaughnessy
Honoraria - Abbvie; Agendia; Amgen; Aptitude Health; AstraZeneca; Bayer; Bristol-Myers Squibb; Celgene; Clovis Oncology; Daiichi Sankyo; Eisai; G1 Therapeutics; Genentech; Gilead Sciences; GRAIL; Halozyme; HERON; Immunomedics; Ipsen; Lilly; Merck; Myriad Pharmaceuticals; Nektar; Novartis; Pfizer; Pharmacyclics; Pierre Fabre; Prime Oncology; Puma Biotechnology; Roche; Samsung; Sanofi; Seagen; Syndax; Synthon; Taiho Oncology; Takeda
Consulting or Advisory Role - Abbvie; Agendia; Amgen; Aptitude Health; AstraZeneca; Bayer; Bristol-Myers Squibb; Celgene; Clovis Oncology; Daiichi Sankyo; Eisai; G1 Therapeutics; Genentech; Gilead Sciences; GRAIL; Halozyme; HERON; Immunomedics; Ipsen; Lilly; Merck; Myriad Pharmaceuticals; Nektar; Novartis; Pfizer; Pharmacyclics; Pierre Fabre; Prime Oncology; Puma Biotechnology; Roche; Samsung; Sanofi; Seagen; Syndax; Synthon; Taiho Oncology; Takeda
Speakers' Bureau - AstraZeneca; Lilly; Novartis; Pfizer
Research Funding - Seagen (Inst)
Travel, Accommodations, Expenses - Abbvie; Agendia; Amgen; AstraZeneca; Celgene; Eisai; GRAIL; Ipsen; Lilly; Myriad Pharmaceuticals; Novartis; Pfizer; Puma Biotechnology; Roche; Sanofi; Seagen
 
Shanu Modi
Honoraria - Daiichi Sankyo/Astra Zeneca; Seagen
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Genentech; GlaxoSmithKline; Lilly; Macrogenics; Puma Biotechnology; Seagen; Zymeworks
Research Funding - AstraZeneca (Inst); Daiichi Sankyo (Inst); Roche/Genentech (Inst); Seagen (Inst)
 
Haeseong Park
Research Funding - Ambrx (Inst); Amgen (Inst); Aprea Therapeutics (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); BJ Bioscience (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Five Prime Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Gossamer Bio (Inst); ImmuneOncia (Inst); Immunomedics (Inst); Incyte (Inst); Jounce Therapeutics (Inst); Lilly (Inst); MabSpace Biosciences (Inst); Macrogenics (Inst); MedImmune (Inst); Medivation (Inst); Merck (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Oncologie (Inst); Pfizer (Inst); PsiOxus Therapeutics (Inst); Puma Biotechnology (Inst); Regeneron (Inst); Roche (Inst); Seagen (Inst); Synermore Biologics (Inst); Taiho Pharmaceutical (Inst); Top Alliance BioScience (Inst); Turning Point Therapeutics (Inst); Vedanta Biosciences (Inst); Vertex (Inst); Xencor (Inst)
Travel, Accommodations, Expenses - Bayer; Daiichi Sankyo; Vedanta Biosciences
 
Amelia McCartney
Honoraria - the limbic
 
Sophia Frentzas
Consulting or Advisory Role - GOG Foundation; MSD Oncology
 
Catherine M. Shannon
No Relationships to Disclose
 
Richard Wilhelm Eek
No Relationships to Disclose
 
Miguel Martin
Honoraria - Lilly; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Seagen
Consulting or Advisory Role - AstraZeneca; Daiichi-Sankyo; Lilly; Novartis; Pfizer; Roche/Genentech
Speakers' Bureau - Lilly/ImClone; Lilly/ImClone; Pierre Fabre; Roche/Genentech
Research Funding - Novartis (Inst); Puma Biotechnology (Inst); Roche (Inst)
Other Relationship - Novartis; Roche
 
Giuseppe Curigliano
Honoraria - Ellipses Pharma
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Daichi-Sankyo; Foundation Medicine; GlaxoSmithKline; Guardant Health; Lilly; Novartis; Pfizer; Roche/Genentech; Samsung; Seagen
Speakers' Bureau - Daiichi Sankyo; Foundation Medicine; Lilly; Novartis; Pfizer; Roche/Genentech; Samsung; Seagen
Research Funding - Merck (Inst)
Travel, Accommodations, Expenses - Pfizer; Roche/Genentech
 
Guy Heinrich Maria Jerusalem
Honoraria - Abbvie; Amgen; AstraZeneca; Bristol-Myers Squibb; Daiichy Sankyo; Lilly; Novartis; Pfizer; Roche
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Lilly; Novartis; Pfizer; Roche
Research Funding - Novartis; Pfizer; Roche
Travel, Accommodations, Expenses - Amgen; AstraZeneca; BMS; Lilly; Medimmune; Merck; Novartis; Pfizer; Roche
 
Chiun-Sheng Huang
No Relationships to Disclose
 
Michael F. Press
Stock and Other Ownership Interests - Torl Biotherapeutics
Consulting or Advisory Role - AstraZeneca; Biocartis; Cepheid; Lilly; Lilly; Merck; Zymeworks
 
Sara M. Tolaney
Consulting or Advisory Role - 4D Pharma; AstraZeneca; Athenex; BeyondSpring Pharmaceuticals; Blueprint Medicines; Bristol-Myers Squibb; Certara Inc; Chugai Pharma; CytomX Therapeutics; Daiichi Sankyo; Eisai; Ellipses Pharma; G1 Therapeutics; Genentech; Immunomedics/Gilead; Infinity Pharmaceuticals; Kyowa Hakko Kirin; Lilly; Merck; Mersana; NanoString Technologies; Nektar; Novartis; Odonate Therapeutics; OncoPep; OncoSec; OncXerna Therapeutics; Paxman; Pfizer; Puma Biotechnology; Reveal Genomics; Samsung Bioepis; Sanofi; Seagen; Zentalis; Zymeworks
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Cyclacel (Inst); Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); Immunomedics (Inst); Lilly (Inst); Merck (Inst); NanoString Technologies (Inst); Nektar (Inst); Novartis (Inst); Odonate Therapeutics (Inst); Pfizer (Inst); Sanofi (Inst); Seagen (Inst)
 
Sara A. Hurvitz
Stock and Other Ownership Interests - Ideal Implant (I); ROM Tech (I)
Research Funding - Ambryx (Inst); Amgen (Inst); Arvinas (Inst); Bayer (Inst); Biomarin (Inst); Cascadian Therapeutics (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dignitana (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Lilly (Inst); Macrogenics (Inst); Merrimack (Inst); Novartis (Inst); OBI Pharma (Inst); Pfizer (Inst); Phoenix Molecular Designs (Inst); Pieris Pharmaceuticals (Inst); Puma Biotechnology (Inst); Radius Health (Inst); Samumed (Inst); sanofi (Inst); Seagen (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - Lilly
Other Relationship - Pfizer; Roche